Breakthrough Properties
A Tishman Speyer & Bellco Capital joint venture.
- Real Estate
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
* | €38.0m | Debt | |
| Total Funding | 000k | ||
Breakthrough Properties is a life science real estate investment firm that focuses on creating environments conducive to scientific innovation and breakthroughs. The company serves clients in the biotechnology and pharmaceutical sectors, providing state-of-the-art facilities that support research and development. Operating in the rapidly growing and under-supplied life science real estate market, Breakthrough Properties leverages a unique collaboration between Tishman Speyer's global real estate expertise and Bellco Capital's biotechnology entrepreneurship. The business model revolves around acquiring, developing, and managing high-quality life science properties, generating revenue through leasing these specialized spaces to leading biotech firms. The firm's flagship project, a 185,000 square foot campus, is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol Myers Squibb.
Keywords: life science, real estate, biotechnology, innovation, investment, development, leasing, Tishman Speyer, Bellco Capital, research facilities.